Due to the correlation of CD80 and CD86 expression in many glomerulopathies, the B7-1(CD80)-CTLA-4 and B7-2(CD86)-CTLA-4 interactions have been proposed as a molecular target in the treatment of these diseases. This evidence concerns the gene CD86 and lipoprotein glomerulopathy.